Notice of Results

RNS Number : 7580K

Verici Dx PLC

06 September 2021

 

Verici Dx plc

("Verici Dx" or the "Company") 

Notice of Results

Investor Briefing

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it will release its unaudited results for the six-month period to 30 June 2021 on Monday 13 September 2021.

Investor briefing

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on Monday 13 September 2021 at 16:30hrs BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00hrs the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow Verici Dx plc on the Investor Meet Company platform will automatically be invited.

Enquiries:

Verici Dx	www.v ericidx .com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
N+1 Singer (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Justin McKeegan / Tom Salvesen
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Sam Allen	Mob: [phone]

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will respond and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ and in conjunction with biological pathways.  Our products and solutions are underpinned by extensive scientific research producing RNA signatures to determine the risk and diagnosis of acute rejection, chronic injury and ultimately failure of the transplant. These RNA signatures also provide valuable information to clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END

 

 

NORLAMPTMTJMBLB